Abstract
Diagnostic laboratories gather phenotypic data through requisition forms, but there is no consensus as to which data are essential for variant interpretation. The ClinGen Cardiomyopathy Variant Curation Expert Panel defined a phenotypic data set for hypertrophic cardiomyopathy (HCM) variant interpretation, with the goal of standardizing requisition forms. Phenotypic data elements listed on requisition forms from nine leading cardiomyopathy testing laboratories were compiled to assess divergence in data collection. A pilot of 50 HCM cases was implemented to determine the feasibility of harmonizing data collection. Laboratory directors were surveyed to gauge potential for adoption of a minimal data set. Wide divergence was observed in the phenotypic data fields in requisition forms. The 50-case pilot showed that although demographics and assertion of a clinical diagnosis of HCM had 86% to 98% completion, specific phenotypic features, such as degree of left ventricular hypertrophy, ejection fraction, and suspected syndromic disease, were completed only 24% to 44% of the time. Nine data elements were deemed essential for variant classification by the expert panel. Participating laboratories unanimously expressed a willingness to adopt these data elements in their requisition forms. This study demonstrates the value of comparing and sharing best practices through an expert group, such as the ClinGen Program, to enhance variant interpretation, providing a foundation for leveraging cumulative case-level data in public databases and ultimately improving patient care.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 589-598 |
| Number of pages | 10 |
| Journal | Journal of Molecular Diagnostics |
| Volume | 23 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 2021 |
Funding
Supported by ClinGen, which is funded by National Human Genome Research Institute (NHGRI) grants U41HG006834 , U41HG009649 , and U41HG009650 and Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) grants U24HD093483 , U24HD093486 , and U24HD093487 . Disclosures: A.M., J.G., T.W., and M.V. are employees and shareholders at Invitae; J.S.W. received research support and consultancy fees from MyoKardia Inc. (outside the submitted work); G.R., M.M., and D.M. are employed by Genedx, a wholly owned subsidiary of Opko Health; C.H. receives consulting fees from MyoKardia, Inc., Novartis, Ambry Genetics, DiNAQOR, and Tenaya; T.J. and C.A. are Ambry employees; J.I. receives research grant support from Myokardia Inc.; B.H.F. is an employee at Sema4; M.F. received travel and honoraria from BioMarin and Genzyme and is an employee and stockholder of Illumina Inc.
ASJC Scopus subject areas
- Pathology and Forensic Medicine
- Molecular Medicine